심정지 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Cardiac Arrest Treatment Market size is expected to reach USD 70.17 Billion in 2034 from USD 31.29 Billion (2025) growing at a CAGR of 9.39% during 2026-2034.

The Global Cardiac Arrest Treatment Market is growing steadily due to rising incidence of cardiovascular diseases worldwide. Cardiac arrest requires immediate intervention through defibrillators, advanced life support, and emergency medications. Increasing awareness about emergency response systems and availability of automated external defibrillators (AEDs) is supporting market growth.

Major growth drivers include advancements in resuscitation devices and growing training programs for CPR and emergency care. Healthcare systems are investing in improving emergency medical infrastructure. Rising prevalence of lifestyle-related risk factors such as obesity and hypertension is further increasing demand for effective treatment solutions. Additionally, supportive government initiatives promoting public access defibrillation programs are strengthening market expansion.

Future prospects remain positive as technological innovations improve survival rates and monitoring capabilities. Emerging markets upgrading emergency healthcare services will create additional opportunities. Companies are focusing on portable and smart defibrillator solutions. As cardiovascular awareness increases globally, the Global Cardiac Arrest Treatment Market is expected to witness consistent growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drugs

• Vasopressors
• Anti-Arrhythmic Drugs
• Anticholinergic Drugs
• Corticosteroids
• Fibrinolytic Drugs
• Beta Blockers
• Others

By Medical Devices

• Defibrillators
• Cardiac Resynchronization Therapy (Crt)
• Others

By Distribution Channels

• Hospitals
• Retail Pharmacies
• Online Pharmacies
• Others

COMPANIES PROFILED

• Bayer AG, Pfizer Inc, GE Healthcare, Amgen Inc, Koninklijke Philips NV, Novartis AG, Abbott, Boston Scientific Corporation, Stryker, BristolMyers Squibb Company
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CARDIAC ARREST TREATMENT MARKET: BY DRUGS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drugs
• 4.2. Vasopressors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Anti-Arrhythmic Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Anticholinergic Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Fibrinolytic Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Beta Blockers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CARDIAC ARREST TREATMENT MARKET: BY MEDICAL DEVICES 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Medical Devices
• 5.2. Defibrillators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Cardiac Resynchronization Therapy (Crt) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CARDIAC ARREST TREATMENT MARKET: BY DISTRIBUTION CHANNELS 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channels
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CARDIAC ARREST TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drugs
  • 7.2.2 By Medical Devices
  • 7.2.3 By Distribution Channels
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drugs
  • 7.3.2 By Medical Devices
  • 7.3.3 By Distribution Channels
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drugs
  • 7.4.2 By Medical Devices
  • 7.4.3 By Distribution Channels
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drugs
  • 7.5.2 By Medical Devices
  • 7.5.3 By Distribution Channels
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drugs
  • 7.6.2 By Medical Devices
  • 7.6.3 By Distribution Channels
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CARDIAC ARREST TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Bayer AG
  • 9.2.2 Pfizer Inc
  • 9.2.3 GE Healthcare
  • 9.2.4 Amgen Inc
  • 9.2.5 Koninklijke Philips N.V
  • 9.2.6 Novartis AG
  • 9.2.7 Abbott
  • 9.2.8 Boston Scientific Corporation
  • 9.2.9 Stryker
  • 9.2.10 Bristol-Myers Squibb Company